109291

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Requestor's Name: Audet, M. Serial Number: 09/736076

Date: 11-14-03 Phone: 305.5039 Art Unit: 1654
11D04

Search Topic:
Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevent citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevent claim(s).

Seq. IDs 15 - 19

STAFF USE ONLY

Date completed: 11-14-03
Searcher: Bever 4 @ 4994
Terminal time: ~~20~~ 1-23
Elapsed time: _____
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
_____ STIC
_____ CM-1
_____ Pre-S

Type of Search
_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure
_____ Bibliographic

Vendors
_____ IG
_____ STN
_____ Dialog
_____ APS
_____ Geninfo
_____ SDC
_____ DARC/Questel
✓ Other CSN

Aud t, Maury

Subject: 09736076-Search of 5 Peptides

In the above application, please search the following 5 sequences: SEQ ID NOS: 15, 16, 17, 18, and 19 (including pending DB's RAPM, RAPN).

Thanks.

Maury

11264

703-305-9039.

Audet, M.
09/736076

FILE 'REGISTRY' ENTERED AT 14:26:52 ON 14 NOV 2003
L1 31 S MLLG[KR]PPF | LGRPPFETS/SQSP

FILE 'HCAPLUS' ENTERED AT 14:28:05 ON 14 NOV 2003
L2 18 S L1

L2 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:765147 HCAPLUS
DOCUMENT NUMBER: 139:241380
TITLE: Expressed sequence tags from cDNA libraries derived from human mRNAs having intact 5' ends and their encoded secreted proteins
INVENTOR(S): Tanaka, Hiroaki; Dumas Milne, Edwards Jean-Baptiste; Giordano, Jean-Yves; Jobert, Severin; Bejanin, Stephane
PATENT ASSIGNEE(S): Genset, Fr.
SOURCE: Can. Pat. Appl., 163 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2343602	AA	20011018	CA 2001-2343602	20010417
CA 2343602	AA	20011018	CA 2001-2343602	20010417
PRIORITY APPLN. INFO.:			US 2000-197873P P	20000418
			CA 2001-2343602 A	20010417

AB The sequences of 5' ESTs and consensus contigated 5' ESTs derived from cDNA libraries derived from mRNAs having intact 5' ends are disclosed. The 5' ESTs and consensus contigated 5' ESTs may be used to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs and consensus contigated 5' ESTs. The 5' ESTs and consensus contigated 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs and consensus contigated 5' ESTs. The 5' ESTs and consensus contigated 5' ESTs may also be used to design expression vectors and secretion vectors. [This abstract record is one of thirteen records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **599342-26-4**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; expressed sequence tags from cDNA libraries derived from human mRNAs having intact 5' ends and their encoded secreted proteins)

L2 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:447168 HCAPLUS
DOCUMENT NUMBER: 139:227956
TITLE: Cell cycle dependent expression of Plk1 in synchronized porcine fetal fibroblasts
AUTHOR(S): Anger, Martin; Kues, Wilfried A.; Klima, Jiri; Mielenz, Manfred; Kubelka, Michal; Motlik, Jan; Esner, Milan; Dvorak, Petr; Carnwath, Joseph W.;

Niemann, Heiner
CORPORATE SOURCE: Institute of Animal Physiology and Genetics, Libechov, Czech Rep.
SOURCE: Molecular Reproduction and Development (2003), 65(3), 245-253
CODEN: MREDEE; ISSN: 1040-452X
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Enzymes of the Polo-like kinase (Plk) family are active in the pathways controlling mitosis in several species. We have cloned cDNA fragments of the porcine homologs of Plk1, Plk2, and Plk3 employing fetal fibroblasts as source. All three partial cDNAs showed high sequence homol. with their mouse and human counterparts and contained the Polo box, a domain characteristic for all Polo kinases. The expression levels of Plk1 mRNA at various points of the cell cycle in synchronized porcine fetal fibroblasts were analyzed by both RT-PCR and the RNase protection assay. Plk1 mRNA was barely detectable in G0 and G1, increased during S phase and peaked after the G2/M transition. A monoclonal antibody was generated against an in vitro expressed porcine Plk1-protein fragment and used to detect changes in Plk1 expression at the protein level. Plk1 protein was first detected by immunoblotting at the beginning of S phase and was highest after the G2/M transition. In summary, the Plk1 expression pattern in the pig is similar to that reported for other species. The absence of Plk1 mRNA and protein appears to be a good marker for G0/G1 and thus for the selection of donor cells for nuclear transfer based somatic cloning.

IT **481546-49-0**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; cDNA sequences of Polo-like kinase (Plk1, Plk2, and Plk3) sequence homologs of pig and cell cycle dependent expression of Plk1 in synchronized porcine fetal fibroblasts)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:334543 HCAPLUS
DOCUMENT NUMBER: 138:350479
TITLE: Protein and cDNA sequences of human protein kinase/protein phosphatase sequence homologs
INVENTOR(S): Ota, Toshio; Isogai, Takao; Nishikawa, Tetsuo; Hayashi, Koji; Otsuka, Kaoru; Yamamoto, Jun-ichi; Ishii, Shizuko; Sugiyama, Tomoyasu; Wakamatsu, Ai; Nagai, Keiichi; Otsuki, Tetsuji; Funahashi, Shin-ichi; Senoo, Chiaki; Nezu, Jun-ichi
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 113 pp., Cont.-in-part of Appl. No. PCT/JP00/05060.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003082776	A1	20030501	US 2002-59585	20020129
JP 2002171977	A2	20020618	JP 2000-196309	20000626
WO 2001009345	A1	20010208	WO 2000-JP5060	20000728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001009319	A1	20010208	WO 2000-JP5065	20000728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1205549	A1	20020515	EP 2000-948282	20000728

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:		
JP 1999-248036	A	19990729
US 1999-159590P	P	19991018
JP 2000-118776	A	20000111
US 2000-183322P	P	20000217
JP 2000-183767	A	20000502
WO 2000-JP5060	A2	20000728
WO 2000-JP5065	W	20000728

AB The invention provides protein and cDNA sequences of human proteins having the kinase and/or phosphatase-like structure from clones which had been isolated and the structures thereof had been determined in the Helix Research Institute (helix clones; Japanese Patent Application Number 2000-183767) was conducted. Twelve novel genes were provided by carrying out homol. search for all the helix clones by using the amino acid sequences of known kinases and phosphatases as queries. The genes are expected to be involved in intracellular signal transduction. The physiol. functions of the inventive genes can be tested by using reporter gene assay systems capable of detecting signal transduction. The proteins of the present invention are useful as target mols. in drug discovery and in the development of new pharmaceuticals.

IT **518362-19-1P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; protein and cDNA sequences of human protein kinase/protein phosphatase sequence homologs)

L2 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:97986 HCAPLUS

DOCUMENT NUMBER: 138:147705
TITLE: Protein and cDNA sequences of human protein kinase SAK and use in modulation of cellular proliferation for treatment of cancer
INVENTOR(S): Hitoshi, Yasumichi; Demo, Susan; Jenkins, Yonchu
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003027756	A1	20030206	US 2001-26021	20011221
WO 2003012055	A2	20030213	WO 2002-US24312	20020731

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-309632P P 20010801
US 2001-26021 A 20011221

AB The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small mol. chemical compns., antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compns. in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

IT **496831-29-9**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of human protein kinase SAK and use in modulation of cellular proliferation for treatment of cancer)

L2 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:55959 HCAPLUS
DOCUMENT NUMBER: 138:84325
TITLE: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
AUTHOR(S): Strausberg, Robert L.; Feingold, Elise A.; Grouse, Lynette H.; Derge, Jeffery G.; Klausner, Richard D.; Collins, Francis S.; Wagner, Lukas;

Shenmen, Carolyn M.; Schuler, Gregory D.; Altschul, Stephen F.; Zeeberg, Barry; Buetow, Kenneth H.; Schaefer, Carl F.; Bhat, Narayan K.; Hopkins, Ralph F.; Jordan, Heather; Moore, Troy; Max, Steve I.; Wang, Jun; Hsieh, Florence; Diatchenko, Luda; Marusina, Kate; Farmer, Andrew A.; Rubin, Gerald M.; Hong, Ling; Stapleton, Mark; Soares, M. Bento; Bonaldo, Maria F.; Casavant, Tom L.; Scheetz, Todd E.; Brownstein, Michael J.; Usdin, Ted B.; Toshiyuki, Shiraki; Carninci, Piero; Prange, Christa; Raha, Sam S.; Loquellano, Naomi A.; Peters, Garrick J.; Abramson, Rick D.; Mullahy, Sara J.; Bosak, Stephanie A.; McEwan, Paul J.; McKernan, Kevin J.; Malek, Joel A.; Gunaratne, Preethi H.; Richards, Stephen; Worley, Kim C.; Hale, Sarah; Garcia, Angela M.; Gay, Laura J.; Hulyk, Stephen W.; Villalon, Debbie K.; Muzny, Donna M.; Sodergren, Erica J.; Lu, Xiuhua; Gibbs, Richard A.; Fahey, Jessica; Helton, Erin; Ketteman, Mark; Madan, Anuradha; Rodrigues, Stephanie; Sanchez, Amy; Whiting, Michelle; Madan, Anup; Young, Alice C.; Shevchenko, Yuriy; Bouffard, Gerard G.; Blakesley, Robert W.; Touchman, Jeffrey W.; Green, Eric D.; Dickson, Mark C.; Rodriguez, Alex C.; Grimwood, Jane; Schmutz, Jeremy; Myers, Richard M.; Butterfield, Yaron S. N.; Krzywinski, Martin I.; Skalska, Ursula; Smailus, Duane E.; Schnerch, Angelique; Schein, Jacqueline E.; Jones, Steven J. M.; Marra, Marco A.

CORPORATE SOURCE: National Cancer Institute, NIH, Bethesda, MD, 20892-2580, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(26), 16899-16903
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The National Institutes of Health Mammalian Gene Collection (MGC) Program is a multiinstitutional effort to identify and sequence a cDNA clone containing a complete ORF for each human and mouse gene. ESTs were generated from libraries enriched for full-length cDNAs and analyzed to identify candidate full-ORF clones, which then were sequenced to high accuracy. The MGC has currently sequenced and verified the full ORF for a nonredundant set of >9000 human and >6000 mouse genes. Candidate full-ORF clones for an addnl. 7800 human and 3500 mouse genes also have been identified. All MGC sequences and clones are available without restriction through public databases and clone distribution networks. [This abstract record is one of eleven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **483718-42-9**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; generation and initial anal. of more than

15,000 full-length human and mouse cDNA sequences)

L2 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:55946 HCAPLUS
DOCUMENT NUMBER: 138:84320
TITLE: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
AUTHOR(S): Strausberg, Robert L.; Feingold, Elise A.; Grouse, Lynette H.; Derge, Jeffery G.; Klausner, Richard D.; Collins, Francis S.; Wagner, Lukas; Shenmen, Carolyn M.; Schuler, Gregory D.; Altschul, Stephen F.; Zeeberg, Barry; Buetow, Kenneth H.; Schaefer, Carl F.; Bhat, Narayan K.; Hopkins, Ralph F.; Jordan, Heather; Moore, Troy; Max, Steve I.; Wang, Jun; Hsieh, Florence; Diatchenko, Luda; Marusina, Kate; Farmer, Andrew A.; Rubin, Gerald M.; Hong, Ling; Stapleton, Mark; Soares, M. Bento; Bonaldo, Maria F.; Casavant, Tom L.; Scheetz, Todd E.; Brownstein, Michael J.; Usdin, Ted B.; Toshiyuki, Shiraki; Carninci, Piero; Prange, Christa; Raha, Sam S.; Loquellano, Naomi A.; Peters, Garrick J.; Abramson, Rick D.; Mullahy, Sara J.; Bosak, Stephanie A.; McEwan, Paul J.; McKernan, Kevin J.; Malek, Joel A.; Gunaratne, Preethi H.; Richards, Stephen; Worley, Kim C.; Hale, Sarah; Garcia, Angela M.; Gay, Laura J.; Hulyk, Stephen W.; Villalon, Debbie K.; Muzny, Donna M.; Sodergren, Erica J.; Lu, Xiuhua; Gibbs, Richard A.; Fahey, Jessica; Helton, Erin; Ketteman, Mark; Madan, Anuradha; Rodrigues, Stephanie; Sanchez, Amy; Whiting, Michelle; Madan, Anup; Young, Alice C.; Shevchenko, Yuriy; Bouffard, Gerard G.; Blakesley, Robert W.; Touchman, Jeffrey W.; Green, Eric D.; Dickson, Mark C.; Rodriguez, Alex C.; Grimwood, Jane; Schmutz, Jeremy; Myers, Richard M.; Butterfield, Yaron S. N.; Krzywinski, Martin I.; Skalska, Ursula; Smailus, Duane E.; Schnerch, Angelique; Schein, Jacqueline E.; Jones, Steven J. M.; Marra, Marco A.
CORPORATE SOURCE: Mammalian Gene Collection (MGC) Program Team, National Cancer Institute, NIH, Bethesda, MD, 20892-2580, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(26), 16899-16903
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The National Institutes of Health Mammalian Gene Collection (MGC) Program is a multiinstitutional effort to identify and sequence a cDNA clone containing a complete ORF for each human and mouse gene. ESTs were generated from libraries enriched for full-length cDNAs and analyzed to identify candidate full-ORF clones, which then were sequenced to high accuracy. The MGC has currently sequenced and

verified the full ORF for a nonredundant set of >9000 human and >6000 mouse genes. Candidate full-ORF clones for an addnl. 7800 human and 3500 mouse genes also have been identified. All MGC sequences and clones are available without restriction through public databases and clone distribution networks. [This abstract record is one of eleven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **480062-88-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; generation and initial anal. of more than 15,000 full-length human and mouse cDNA sequences)

L2 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:889007 HCAPLUS
DOCUMENT NUMBER: 138:347
TITLE: Sequences of genetic markers for evaluating estrogenic activity
INVENTOR(S): Barbosa, Miguel S.; Brady, Helen A.; Chan, Kyle W. H.; Pardinas, Jose R.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002093124	A2	20021121	WO 2002-US14597	20020510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003054332	A1	20030320	US 2001-853544	20010510

PRIORITY APPLN. INFO.: US 2001-853544 A 20010510

AB Methods are provided for evaluating estrogenic and antiestrogenic effects of candidate therapeutic agents. Such methods are generally based on assays to detect modulation of estrogen-regulated marker expression in one or more specific cell types. Agents identified using such methods may be used, for example, in the prevention and treatment of diseases such as osteoporosis, cardiovascular disease and cancer. In addition, the gene discovery approaches discussed have identified a using gene profile for estrogen regulation in vascular endothelial cells. This gene profile will allow characterization of the effects of potential SERMs in the cardiovascular system this gene profile and the assays established with these genes will enable more extensive evaluation of tissue specific properties of SERM compds. and provide a better understanding of cardiovascular effects

of SERMs.

IT **402712-46-3**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; sequences of genetic markers for evaluating estrogenic activity)

L2 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:616256 HCAPLUS
DOCUMENT NUMBER: 137:181594
TITLE: Dominant-negative variants of human protein kinases that inhibit the phosphorylation activity of their active enzyme isoforms
INVENTOR(S): Levine, Zurit; Bernstein, Jeanne
PATENT ASSIGNEE(S): Compugen Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 170 pp., Cont.-in-part of U.S. Ser. No. 724,676.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002110811	A1	20020815	US 2001-771161	20010126

PRIORITY APPLN. INFO.:
IL 2000-135619 A 20000512
IL 2000-136776 A 20000615
US 2000-724676 A2 20001128

AB The present invention concerns 91 nucleic acid sequences and amino acid sequences of variants of various human kinases, i.e. of sequences which inhibit activity of kinases in a dominant manner. The variants lack a domain or region required for phosphorylation, and thus may be dominant-neg. kinases obtained by alternative splicing of known original sequences of the kinase genes. The novel dominant-neg. kinase variants of the invention are not merely artificially truncated forms, fragments or mutations of known genes, but rather novel sequences which naturally occur within the body of individuals. The invention also concerns pharmaceutical compns. and detection methods using these sequences.

IT **449226-29-3**
RL: PRP (Properties)
(unclaimed protein sequence; dominant-neg. variants of human protein kinases that inhibit the phosphorylation activity of their active enzyme isoforms)

L2 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:521988 HCAPLUS
DOCUMENT NUMBER: 137:74472
TITLE: Human cDNAs for NF-kB activating proteins
INVENTOR(S): Matsuda, Akio; Honda, Goichi; Muramatsu, Shuji; Nagano, Yukiko
PATENT ASSIGNEE(S): Asahi Kasei Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 841 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053737	A1	20020711	WO 2001-JP11389	20011225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1354950	A1	20031022	EP 2001-272530	20011225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003170719	A1	20030911	US 2002-42211	20020107

PRIORITY APPLN. INFO.:		
JP 2000-402288	A	20001228
JP 2001-88912	A	20010326
JP 2001-254018	A	20010824
US 2000-258315P	P	20001228
US 2001-278640P	P	20010326
US 2001-314385P	P	20010824
US 2001-24298	A2	20011221
WO 2001-JP11389	W	20011225

AB Novel human proteins having an NF-kB activating effect, cDNAs, recombinant expression, use in diagnosis and drug screening, are disclosed. Use of antibodies, ribozymes, or antisense oligonucleotides for those cDNAs and proteins for treatment of inflammation, autoimmune disease, infection, cancer, bone disease, AIDS, neurodegenerative disease, or ischemic disease, is claimed. From a cDNA library prepared from human lung fibroblasts, cDNAs encoding proteins having an effect of activating NF-kB were cloned and their DNA and amino acid sequence deduced therefrom were determined

IT **440684-40-2P**, Protein (human NF-kB activating)
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BUU (Biological use, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human cDNAs for NF-kB activating proteins)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	2002:509654 HCAPLUS Correction of: 2002:10496
DOCUMENT NUMBER:	137:58696 Correction of: 136:49428
TITLE:	Human nucleic acids and their encoded proteins and antibodies for the diagnosis and therapy of ovarian cancer
INVENTOR(S):	Birse, Charles E.; Rosen, Craig A.
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., USA
SOURCE:	PCT Int. Appl., 2922 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 91
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000677	A1	20020103	WO 2001-US18569	20010607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041411	A5	20010820	AU 2001-41411	20010208

PRIORITY APPLN. INFO.: US 2000-209467P P 20000607
US 2000-241221P P 20001020
US 2000-241786P P 20001020

AB The present invention relates to novel ovarian cancer-related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such antigens for detecting disorders of the ovary, particularly the presence of ovarian cancer and ovarian cancer metastases. More specifically, 2185 isolated ovarian cancer-associated cDNA mols. are provided encoding novel polypeptides: Novel ovarian cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian cancer-associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compns. for inhibiting the production and function of the polypeptides of the present invention. The Sequence Listing was provided as an electronic file, but was not made available in the release of this patent.

IT **439729-90-5P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human nucleic acids and their encoded proteins and antibodies for the diagnosis and therapy of ovarian cancer)

L2 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:315483 HCAPLUS
DOCUMENT NUMBER: 136:335268
TITLE: Short peptides which selectively modulate the

activity of serine/threonine kinases
INVENTOR(S): Ben-sasson, Shmuel A.
PATENT ASSIGNEE(S): The Children's Medical Center Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U. S. 6,174,993.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002049301	A1	20020425	US 2000-736076	20001213
US 6174993	B1	20010116	US 1997-861338	19970521

PRIORITY APPLN. INFO.: US 1997-861338 A2 19970521
OTHER SOURCE(S): MARPAT 136:335268

AB Peptides are disclosed which are peptide derivs. of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the invention. The peptides can be used for the treatment of a wide variety of diseases.

IT **216489-73-5P 216489-75-7P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide modulators of serine/threonine kinases)

IT **416847-00-2 416847-01-3 416847-41-1 416847-48-8**
RL: PRP (Properties)
(unclaimed sequence; short peptides which selectively modulate the activity of serine/threonine kinases)

L2 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:746842 HCAPLUS
DOCUMENT NUMBER: 136:51338
TITLE: Cloning and characterization of Plx2 and Plx3, two additional polo-like kinases from Xenopus laevis
AUTHOR(S): Duncan, Peter I.; Pollet, Nicolas; Niehrs, Christof; Nigg, Erich A.
CORPORATE SOURCE: Department of Cell Biology, Max Planck Institute for Biochemistry, Martinsried, D-82152, Germany
SOURCE: Experimental Cell Research (2001), 270(1), 78-87
CODEN: ECREAL; ISSN: 0014-4827
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Members of the family of Polo-like kinases are implicated in the regulation of cell cycle progression in all eukaryotes. In Xenopus laevis, only 1 member of this family, Plx1, has previously been described. Here we report the cloning and characterization of X. laevis Plx2 and Plx3, the likely homologs of mammalian Plk2 (Snk) and Plk3 (Fnk/Prk), resp. RNA expression studies indicate that all 3 Xenopus Plks are present in both oocytes and unfertilized eggs. Further anal. by in situ hybridization revealed that Plx1 RNA is ubiquitously expressed in early embryos, but shows more restricted

expression at later stages. In contrast, Plx2 and Plx3 expression is highly restricted in both early and late-stage embryos. Using Plx-specific antisera, Plx1 and Plx3 polypeptides could readily be detected on immunoblots of oocyte and egg exts. Both Plx1 and Plx3 protein levels remained virtually constant during oocyte maturation. However, whereas Plx1 is more active in M phase than in I phase, Plx3 protein and activity levels remained constant upon release of meiotic metaphase II-arrested egg exts. into interphase. Finally, microinjection of in vitro-transcribed RNAs for Plx1, Plx2, and Plx3 increased the rate of progesterone-induced oocyte maturation, and concomitantly, all 3 kinases became activated. Conversely, overexpression of the corresponding catalytically inactive kinases delayed maturation. This suggests that, at least in oocytes, all 3 kinases may be regulated by similar mechanisms, and they may also share common substrates. However, the strikingly restricted pattern of expression of Plx2 and Plx3 observed in embryos strongly suggests that individual Plk family members perform at least partly distinct functions at later stages of development. (c) 2001 Academic Press.

IT **382721-00-8**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; cloning and characterization of two addnl. polo-like kinases from frog eggs and embryos)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:629826 HCAPLUS
DOCUMENT NUMBER: 136:211644
TITLE: Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase
AUTHOR(S): Liby, Karen; Wu, Huiyun; Ouyang, Bin; Wu, Shecao; Chen, Jie; Dai, Wei
CORPORATE SOURCE: Department of Cell Biology, University of Cincinnati College of Medicine, USA
SOURCE: DNA Sequence (2001), 11(6), 527-533
CODEN: DNSEES; ISSN: 1042-5179
PUBLISHER: Harwood Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Murine serum inducible kinase (mSnk) was recently cloned and characterized as an early-growth response gene involved in cell proliferation. Here we report the isolation and characterization of its human homolog, named hSnk. Sequence comparison shows that hSnk is highly conserved and its deduced protein sequence shares a significant amino acid identity with mSnk and rSnk proteins, as well as with other polo family kinase gene products. A survey of hSnk expression reveals that while a wide variety of human tissues express a low to moderate level of hSnk transcripts, fetal tissues, testis, and spleen express the most abundant hSnk transcripts. In addition, serum stimulation rapidly induces hSnk expression in fibroblast cells, reaching the peak level of induction within one hour post treatment. Considering that Plk and Prk, two other known human polo-family kinases, control cell cycle checkpoint and cell cycle progression, our current observations suggest that hSnk may also play an important role in cells undergoing rapid cell division

or having a high mitotic index.

IT **402712-46-3**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; identification of the human homolog of the early-growth response gene Snk, encoding a serum-inducible kinase)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:106056 HCAPLUS
DOCUMENT NUMBER: 134:188986
TITLE: Human expressed sequence tags and primers for synthesizing full-length cDNAs
INVENTOR(S): Ota, Toshio; Isogai, Takao; Nishikawa, Tetsuo; Hayashi, Kohji; Saito, Kaoru; Yamamoto, Junichi; Ishii, Shizuko; Sugiyama, Tomoyasu; Wakamatsu, Ai; Nagai, Keiichi; Otsuki, Tetsuji
PATENT ASSIGNEE(S): Helix Research Institute, Japan
SOURCE: Eur. Pat. Appl., 2527 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074617	A2	20010207	EP 2000-116126	20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002171977	A2	20020618	JP 2000-196309	20000626
EP 1205549	A1	20020515	EP 2000-948282	20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2002191363	A2	20020709	JP 2000-280990	20000728

PRIORITY APPLN. INFO.:

JP 1999-248036	A	19990729
JP 1999-300253	A	19990827
JP 2000-118776	A	20000111
JP 2000-183767	A	20000502
JP 2000-241899	A	20000609
US 1999-159590P	P	19991018
US 2000-183322P	P	20000217
WO 2000-JP5065	W	20000728

AB Primers for synthesizing full-length cDNAs and their use are provided. The invention provides 5'-end sequences for 5602 partial cDNA sequences (expressed sequence tags, ESTs) and 3'-end sequences for 4970 of these clones. Furthermore, primers for synthesizing the full-length cDNA have been provided to clarify the function of the protein encoded by the cDNA. The full-length cDNA sequences s of the present invention containing the translation start site provides information useful for analyzing the functions of the proteins. Tissue- and cell-specific expression patterns are also provided. [This abstract record is one of 6 records for this patent necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **326937-52-4**, Protein (human clone PLACE1011923)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; human expressed sequence tags and primers for synthesizing full-length cDNAs)

L2 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:139942 HCAPLUS
DOCUMENT NUMBER: 130:192783
TITLE: Cloning and cDNA sequence of human serum-inducible kinase Snk
INVENTOR(S): Anderson, Karen M.; Jackson, Jeffrey R.; Hansbury, Michael J.; Nerurkar, Sandhya S.; Roshak, Amy K.; Bouzyk, Mark
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909146	A1	19990225	WO 1998-US17248	19980820
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6063609	A	20000516	US 1998-136282	19980820
EP 1007645	A1	20000614	EP 1998-942152	19980820
R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
JP 2001514882	T2	20010918	JP 2000-509813	19980820
US 6245544	B1	20010612	US 2000-505744	20000216

PRIORITY APPLN. INFO.: US 1997-56112P P 19970820
US 1998-136282 A3 19980820
WO 1998-US17248 W 19980820

AB The serum-inducible kinase (Snk) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. The nucleotide sequence of human Snk is a cDNA sequence and comprises an open reading frame encoding a polypeptide of 685 amino acids that is structurally related to other proteins of the Polo-like kinase family and having homol. and/or structural similarity with murine serum-inducible kinase. The gene of the present invention maps to human chromosome 5d12.1-q13.2/D5S491-D5S427. Also disclosed are methods for utilizing Serum Inducible Kinase (Snk) polypeptides and polynucleotides in therapy, and diagnostic assays for such.

IT **220748-32-3P**
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; cloning and cDNA sequence of human serum-inducible kinase Snk)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:9924 HCAPLUS
DOCUMENT NUMBER: 130:77973
TITLE: Disease associated protein kinases of human and their cDNA sequences
INVENTOR(S): Bandman, Olga; Hillman, Jennifer L.; Corley, Neil C.; Guegler, Karl J.; Lal, Preeti; Goli, Surya K.; Shah, Purvi
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858052	A2	19981223	WO 1998-US12813	19980619
WO 9858052	A3	19990610		
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5885803	A	19990323	US 1997-878989	19970619
AU 9881547	A1	19990104	AU 1998-81547	19980619
EP 1007692	A2	20000614	EP 1998-931407	19980619
R: BE, DE, ES, FR, GB, IT, NL				
US 6207148	B1	20010327	US 1999-272796	19990319
US 2003170219	A1	20030911	US 2001-769970	20010124

PRIORITY APPLN. INFO.:
US 1997-878989 A2 19970619
WO 1998-US12813 W 19980619
US 1999-272796 A3 19990319

AB The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases. The amino acid sequences and cDNA sequences of some human disease-associated protein kinases are presented.

IT **218611-29-1**
RL: ANT (Analyte); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; disease associated protein kinases of human and their cDNA sequences)

L2 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:790656 HCAPLUS
DOCUMENT NUMBER: 130:22236
TITLE: Short peptides which selectively modulate the activity of serine/threonine kinases
INVENTOR(S): Ben-Sasson, Shmuel A.
PATENT ASSIGNEE(S): The Children's Medical Center Corp., USA; Yissum Research Development Company of the Hebrew
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9853050	A2	19981126	WO 1998-US10319	19980520
WO 9853050	A3	19990225		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6174993	B1	20010116	US 1997-861338	19970521
AU 9875833	A1	19981211	AU 1998-75833	19980520
AU 734642	B2	20010621		
EP 983346	A2	20000308	EP 1998-923571	19980520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002500649	T2	20020108	JP 1998-550580	19980520
US 2002028772	A1	20020307	US 2000-735274	20001211
US 2003004103	A1	20030102	US 2001-12035	20011211

PRIORITY APPLN. INFO.:		
US 1997-861338	A2	19970521
WO 1998-US10319	W	19980520
US 2000-735274	A2	20001211

AB Disclosed are peptides which are peptide derivs. of the HJ loop of a serine/threonine kinase. Modified peptides derivs. are provided from the modified sequence or subsequence of the HJ loop of such kinases as RAF, cAMP-dependent kinase, protein kinase C, the G protein-coupled receptor kinases βARK1, βBARK2, GRK1 and GRKs4-6, calmodulin-dependent kinase, and Polo. The peptides can modulate the activity of the serine/threonine kinase. For example, peptide derivs. of the HJ loop of Raf and Polo inhibit the proliferation of bovine aortic cells and the transformed mouse cell lines MS1 and/or SVR cells in vitro at concns. as low as 10 μM. Further examples include (1) inhibition of the production of collagen by fetal lung fibroblasts by an HJ peptide deriv of activin/TGFβR and (2) morphol. changes in B16 melanoma cells by an HJ peptide derivative of integrin-linked kinase ILK. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.

IT **216489-73-5 216489-75-7 216489-77-9**
216489-79-1 216489-81-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(Polo kinase-derived; short peptides which selectively modulate the activity of serine/threonine kinases)

IT **216490-49-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(SNK kinase-derived; short peptides which selectively modulate

the activity of serine/threonine kinases)

L2 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:444118 HCAPLUS
DOCUMENT NUMBER: 119:44118
TITLE: Identification of an early-growth-response gene encoding a novel putative protein kinase
AUTHOR(S): Simmons, Daniel L.; Neel, Benjamin G.; Stevens, Ryan; Evett, Gary; Erikson, Raymond L.
CORPORATE SOURCE: Dep. Chem., Brigham Young Univ., Provo, UT, 84602, USA
SOURCE: Molecular and Cellular Biology (1992), 12(9), 4164-9
CODEN: MCEBD4; ISSN: 0270-7306
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Early-growth-response genes, also known as immediate-early genes, play important roles in regulating cell proliferation. A new type of early-growth-response gene product, a 77,811-Da putative serine/threonine kinase, was identified which is highly inducible by serum and phorbol ester. MRNA encoding this putative kinase is markedly elevated within 1 h after treatment with mitogen, and this induction is synergistically increased by cycloheximide. Dexamethasone blocks serum induction of the kinase mRNA, as does transformation by v-Ki-ras. The kinase mRNA was detected in mouse brain, lung, and heart. This new putative kinase, called Snk, for serum-inducible kinase, showed similarity in its proposed catalytic domain to many other protein kinases; however, no other kinase showed enough sequence similarity with Snk to suggest the existence of a common function. Hence, Snk represents a new type of protein kinase involved in the early mitogenic response whose activity is transcriptionally and posttranscriptionally regulated.
IT **148466-70-0**
RL: PRP (Properties); BIOL (Biological study)
(amino acid sequence of, complete)

E1 THROUGH E25 ASSIGNED

FILE 'REGISTRY' ENTERED AT 14:29:04 ON 14 NOV 2003
L3 25 SEA FILE=REGISTRY ABB=ON PLU=ON (216489-73-5/BI OR 216489-75-7/BI OR 402712-46-3/BI OR 148466-70-0/BI OR 216489-77-9/BI OR 216489-79-1/BI OR 216489-81-5/BI OR 216490-49-2/BI OR 218611-29-1/BI OR 220748-32-3/BI OR 326937-52-4/BI OR 382721-00-8/BI OR 416847-00-2/BI OR 416847-01-3/BI OR 416847-41-1/BI OR 416847-48-8/BI OR 439729-90-5/BI OR 440684-40-2/BI OR 449226-29-3/BI OR 480062-88-2/BI OR 481546-49-0/BI OR 483718-42-9/BI OR 496831-29-9/BI OR 518362-19-1/BI OR 599342-26-4/BI)

L4 25 L1 AND L3

L4 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **599342-26-4** REGISTRY
CN Protein (human clone CA2343602-SEQID-15222 N-terminal fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3220: PN: CA2343602 SEQID: 15222 claimed protein
CI MAN

SQL 90

```
SEQ      1 MELKVGDFGL AARLEPLEHR RRTICGTPNY LSPEVLXKXG HGCESXIWAL
        51 GCVMYTMLLG RPPFETTKSQ RNLQVHKGNN VYNAILIAGS
                ==== ====
HITS AT:   57-64
```

REFERENCE 1: 139:241380

L4 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **518362-19-1** REGISTRY
CN Protein (human clone C-PLACE1011923 protein kinase/protein phosphatase sequence homolog) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 14: PN: US20030082776 SEQID: 14 claimed protein
CI MAN
SQL 469

```
SEQ      1 MELKVGDFGL AARLEPLEHR RRTICGTPNY LSPEVLNKQG HGCESDIWAL
        51 GCVMYTMLLG RPPFETTNLK ETYRCIREAR YTMPSSLLAP AKHLIASMLS
                ==== ====
       101 KNPEDRPSLD DIIRHDFFLQ GFTPDRLSSS CCHTVPDFHL SSPAKNFFKK
       151 AAAALFGGKK DKARYIDTHN RVSKEDEDIY KLRHDLKKTS ITQQPSKHRT
       201 DEELQPPTTT VARSGTPAVE NKQQIGDAIR MIVRGTLGSC SSSSECLEDS
       251 TMGSVADTVA RVLRGCLENM PEADCIPKEQ LSTSFQWVTK WVDYSNKYGF
       301 GYQLSDHTVG VLFNNGAHMS LLPDKKTVHY YAELGQCSVF PATDAPEQFI
       351 SQVTVLKYFS HYMEENLMDG GDLPSVTDIR RPRLYLLQWL KSDKALMMLF
       401 NDGTFQVNFY HDHTKIIICS QNEEYLLTYI NEDRISTTFR LTTLLMSGCS
       451 SELKNRMEYA LNMLLQRCN
HITS AT:   57-64
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:350479

L4 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **496831-29-9** REGISTRY
CN 5: PN: US20030027756 FIGURE: 2 unclaimed sequence (9CI) (CA INDEX NAME)
CI MAN
SQL 400

```
SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGGDS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                  ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFYP DRLSSSCCHT
       351 VPDFWLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
HITS AT:   273-280
```

REFERENCE 1: 138:147705

L4 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **483718-42-9** REGISTRY
CN Serum-inducible kinase (mouse strain FVB/N clone MGC:7061

IMAGE:3156743) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAH34513
CN GenBank AAH34513 (Translated from: GenBank BC034513)
CI MAN
SQL 682

SEQ 1 MELLRTITYQ PAAGTKMCEQ ALGKACGGDS KKKRPQQPSE DGQPQAQVTP
51 AAPHHHHHHS HSGPEISRII VDPTTGKRYC RGKVLGKGGF AKCYEMTDLT
101 NNKVYAAKII PHSRVAKPHQ REKIDKEIEL HRLLHHKHVV QFYHYFEDKE
151 NIYILLEYCS RRSMAHILKA RKVLTEPEVR YYLRQIVSGL KYLHEQEILH
201 RDLKLGNFII NEAMELKVGD FGLAARLEPL EHRRRTICGT PNYLSPEVLN
251 KQGHGCESDI WALGCVMYTM LLGRPPFETT NLKETYRCIR EARYTMPSSL
= =======
301 LAPAKHLIAS MLSKNPEDRP SLDDIIRHDF FLQGFTPDRL SSSCCHTVPD
351 FHLSSPAKNF FKKAAAALFG GKKDKARYND THNKVSKEDE DIYKLRHDLK
401 KVSITQQPSK HRADEEPQPP PTTVARSGTS AVENKQQIGD AIRMIVRGTL
451 GSCSSSSECL EDSTMGSVAD TVARVLRGCL ENMPEADCIP KEQLSTSFQW
501 VTKWVDYSNK YGFGYQLSDH TVGVLFNNGA HMSLLPDKKT VHYYAELGQC
551 SVFPATDAPE QFISQVTVLK YFSHYMEENL MDGGDLPSVT DIRRPRLYLL
601 QWLKSDKALM MLFNDGTFQV NFYHDHTKII ICNQSEEYLL TYINEDRIST
651 TFRLTTLLMS GCSLELKNRM EYALNMLLQR CN
HITS AT: 270-277

REFERENCE 1: 138:84325

L4 ANSWER 5 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **481546-49-0** REGISTRY
CN Protein (swine Polo-like kinase Plk2 sequence homolog fragment)
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAK27154
CN GenBank AAK27154 (Translated from: GenBank AF348424)
CN Protein (Sus scrofa Polo-like kinase Plk2 sequence homolog fragment)
CI MAN
SQL 316

SEQ 1 PEVLNKQGHG CESDIWALGC VMYTMLLGRP PFETTNLKET YRCIREARYT
====== ==
51 MPSSLLAPAK HLIASMLSKN PEDRPSLDDI IRHEFFLQGF TPDRLSSSCC
101 HTVPDFHLSS PAKNFFKKAA AALFGGKKDK ARYIDTHNRV SKEDEEIYKL
151 RHDLKKTSIT QQPSKHRTDE ELQPPTTTVA RSGTPAVENK QQIGDAIRMI
201 VRGTLGSCSS SSECLEDSTM GSVADTVARV LRGCLENMPE ADCIPKEQLS
251 TSFQWVTKWV DYSNKYGFGY QLSDHTVGVL FNNGAHMSLL PDKKTVHYYA
301 ELGQCSVFPA TDAPEQ
HITS AT: 25-32

REFERENCE 1: 139:227956

L4 ANSWER 6 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **480062-88-2** REGISTRY
CN (Protein for MGC:10589) (human clone MGC:10589 IMAGE:3831747) (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN GenBank AAH13879
CN GenBank AAH13879 (Translated from: GenBank BC013879)
CI MAN
SQL 685

```
SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                 ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT
       351 VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
       401 DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
       451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
       501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL
       551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
       601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
       651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT:   273-280

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  138:84320

L4   ANSWER 7 OF 25  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   449226-29-3  REGISTRY
CN   249: PN: US20020110811 SEQID: 249 unclaimed protein (9CI)  (CA INDEX
     NAME)
CI   MAN
SQL  685

SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGGDS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                 ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT
       351 VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
       401 DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
       451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
       501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL
       551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
       601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
       651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT:   273-280

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  137:181594

L4   ANSWER 8 OF 25  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   440684-40-2  REGISTRY
CN   Protein (human NF-kB activating) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   39: PN: WO02053737 SEQID: 101 claimed protein
CI   MAN
SQL  685
```

```
SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                 ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT
       351 VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
       401 DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
       451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
       501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL
       551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
       601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
       651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT:   273-280

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  137:74472

L4   ANSWER 9 OF 25  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   439729-90-5  REGISTRY
CN   Ovary-associated antigen (human clone HAOSM08 fragment) (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   3122: PN: WO0200677 SEQID: 3124 claimed protein
CI   MAN
SQL  753

SEQ      1 AVTWCRVSSL RPLPASPYIR LRRALSLAQV DRXGASRHQR QGCEDHGRLG
        51 RVTAPRGWQR AVRGGKATME LLRTITYQPA ASTKMCEQAL GKGCGADSKK
       101 KRPPQPPEES QPPQSQAQVP PAAPHHHHHH SHSGPEISRI IVDPTTGKRY
       151 CRGKVLGKGG FAKCYEMTDL TNNKVYAAKI IPHSRVAKPH QREKIDKEIE
       201 LHRILHHKHV VQFYHYFEDK ENIYILLEYC SRRSMAHILK ARKVLTEPEV
       251 RYYLRQIVSG LKYLHEQEIL HRDLKLGNFF INEAMELKVG DFGLAARLEP
       301 LEHRRRTICG TPNYLSPEVL NKQGHGCESD IWALGCVMYT MLLGRPPFET
                                                   ========
       351 TNLKETYRCI REARYTMPSS LLAPAKHLIA SMLSKNPEDR PSLDDIIRHD
       401 FFLQGFTPDR LSSSCCHTVP DFHLSSPAKN FFKKAAAALF GGKKDKARYI
       451 DTHNRVSKED EDIYKLRHDL KKTSITQQPS KHRTDEELQP PTTTVARSGT
       501 PAVENKQQIG DAIRMIVRGT LGSCSSSSEC LEDSTMGSVA DTVARVLRGC
       551 LENMPEADCI PKEQLSTSFQ WVTKWVDYSN KYGFGYQLSD HTVGVLFNNG
       601 AHMSLLPDKK TVHYYAELGQ CSVFPATDAP EQFISQVTVL KYFSHYMEEN
       651 LMDGGDLPSV TDIRRPRLYL LQWLKSDKAL MMLFNDGTFQ VNFYHDHTKI
       701 IICSQNEEYL LTYINEDRIS TTFRLTTLLM SGCSSELKNR MEYALNMLLQ
       751 RCN
HITS AT:   341-348

REFERENCE   1:  137:58696

L4   ANSWER 10 OF 25  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   416847-48-8  REGISTRY
CN   L-Glutamic acid, L-methionyl-L-leucyl-L-leucylglycyl-L-lysyl-L-
     prolyl-L-prolyl-L-phenylalanyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   47: PN: US20020049301 SEQID: 17 unclaimed sequence
SQL  9
```

SEQ 1 MLLGKPPFE
========
HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 11 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **416847-41-1** REGISTRY
CN L-Glutamic acid, glycyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 37: PN: US20020049301 SEQID: 57 unclaimed sequence
SQL 10

SEQ 1 GMLLGRPPFE
========
HITS AT: 2-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 12 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **416847-01-3** REGISTRY
CN L-Serine, L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L-α-glutamyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: US20020049301 SEQID: 19 unclaimed sequence
SQL 11

Seq. 19 Cl 5

SEQ 1 MLLGRPPFET S
========== =
HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 13 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **416847-00-2** REGISTRY
CN L-Serine, L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L-α-glutamyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020049301 SEQID: 18 unclaimed sequence
SQL 9

Seq. 18 Cl 4

SEQ 1 LGRPPFETS
=========
HITS AT: 1-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 14 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **402712-46-3** REGISTRY
CN Kinase (phosphorylating), gene Snk protein (human gene Snk) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAC14573
CN GenBank AAC14573 (Translated from: GenBank AF059617)
CN Serum-inducible kinase (human)
CI MAN
SQL 685

```
SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGGDS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                  ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT
       351 VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
       401 DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
       451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
       501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL
       551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
       601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
       651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT:   273-280
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:347

REFERENCE 2: 136:211644

L4 ANSWER 15 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **382721-00-8** REGISTRY
CN Kinase (phosphorylating), gene Snk protein (Xenopus laevis gene Plx2) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN GenBank AAL30175
CN GenBank AAL30175 (Translated from: GenBank AF357840)
CN Polo-like kinase 2 (Xenopus laevis gene Plx2)
CI MAN
SQL 666

```
SEQ      1 MELLRNIAYQ PSSGGKMCEQ ALGRVCDPDR RWKVPGDGEP IHHSCSATDV
        51 SRIITDPGTG RRYCRGKVLG KGGFAKCYEM KDLTTNKIYA AKIIPHSRVS
       101 KPHQREKIDK EIELHRTLNH RHVVQFYHYF EDKENIYILM EYCGRRSMAH
       151 ILKTRKVLTD PEVRYYLKQI VSGLKYLHEQ EILHRDLKLG NFFINESMEL
       201 KVGDFGLAAR LEPLEQRRRT ICGTPNYLSP EVLNKQGHGC ESDIWALGCV
       251 MYTMLLGRPP FETTNLKETY KCIREARYSL PSSLMTSAKH LIASMLSRNP
              ======= =
       301 EDRPSLDEIT QHDFFTQGFT PERLPTTCCH TAPDFHLSSP AKNFFKKAAA
       351 ALFGGKKEKS KYLDNHNKLP KEDEVIYKLR QGLQKNTISH QRHNPRTDEE
       401 IKTISKSDVL VERADKQHMG DTIHMIVRGT LGSCSSSSEC LEDSTMGTVA
       451 DTVARVLKDC LEKMPDADAI PKEQIDTSFH WVTKWVDYSN KYGFGYQLSD
       501 HTVGVLFNNG AHMSFLPDKK TVHYYAELGQ CSVFPATEAP EQFISQVTVL
       551 KYFSHYMEEN LMDGGDLPSV TDVCRPRLYL LQWLKSDKAL MMLFNDGTFQ
```

```
       601 VNFYHDHTKI IIANQNDEYV LTYINEDRMS TTFHLSTLLI SGGSSDLKNR
       651 MEYALNMLLQ RCNEVA
HITS AT:    254-261

REFERENCE   1:  136:51338

L4   ANSWER 16 OF 25  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   326937-52-4  REGISTRY
CN   Protein (human clone PLACE1011923) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1057: PN: EP1074617 SEQID: 15726 claimed protein
CI   MAN
SQL  469

SEQ      1 MELKVGDFGL AARLEPLEHR RRTICGTPNY LSPEVLNKQG HGCESDIWAL
        51 GCVMYTMLLG RPPFETTNLK ETYRCIREAR YTMPSSLLAP AKHLIASMLS
                ==== ====
       101 KNPEDRPSLD DIIRHDFFLQ GFTPDRLSSS CCHTVPDFHL SSPAKNFFKK
       151 AAAALFGGKK DKARYIDTHN RVSKEDEDIY KLRHDLKKTS ITQQPSKHRT
       201 DEELQPPTTT VARSGTPAVE NKQQIGDAIR MIVRGTLGSC SSSSECLEDS
       251 TMGSVADTVA RVLRGCLENM PEADCIPKEQ LSTSFQWVTK WVDYSNKYGF
       301 GYQLSDHTVG VLFNNGAHMS LLPDKKTVHY YAELGQCSVF PATDAPEQFI
       351 SQVTVLKYFS HYMEENLMDG GDLPSVTDIR RPRLYLLQWL KSDKALMMLF
       401 NDGTFQVNFY HDHTKIIICS QNEEYLLTYI NEDRISTTFR LTTLLMSGCS
       451 SELKNRMEYA LNMLLQRCN
HITS AT:    57-64

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  134:188986

L4   ANSWER 17 OF 25  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   220748-32-3  REGISTRY
CN   Kinase (phosphorylating), protein, Snk (human) (9CI)  (CA INDEX
     NAME)
CI   MAN
SQL  685

SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                  ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT
       351 VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
       401 DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
       451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
       501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYYAEL
       551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
       601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
       651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT:    273-280

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  130:192783
```

L4 ANSWER 18 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **218611-29-1** REGISTRY
CN Kinase (phosphorylating), protein (human clone 39043 disease-associated isoform DAPK-1) (9CI) (CA INDEX NAME)
CI MAN
SQL 685

```
SEQ      1 MELLRTITYQ PAASTKMCEQ ALGKGCGADS KKKRPPQPPE ESQPPQSQAQ
        51 VPPAAPHHHH HHSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
       101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
       151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRQIV SGLKYLHEQE
       201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
       251 VLNKQGHGCE SDIWALGCVM YTMLLGRPPF ETTNLKETYR CIREARYTMP
                                  ========
       301 SSLLAPAKHL IASMLSKNPE DRPSLDDIIR HDFFLQGFTP DRLSSSCCHT
       351 VPDFHLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
       401 DLKKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
       451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
       501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTAHYYAEL
       551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
       601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
       651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT:  273-280
```

REFERENCE 1: 130:77973

L4 ANSWER 19 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216490-49-2** REGISTRY
CN L-α-Glutamine, N-(1-oxotetradecyl)glycyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)
SQL 10

```
SEQ      1 GMLLGRPPFE
            ========
HITS AT:  2-9
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 20 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216489-81-5** REGISTRY
CN L-Serinamide, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L-α-glutamyl-L-threonyl-, phenylmethyl ester (9CI) (CA INDEX NAME)
SQL 11

```
SEQ      1 MLLGRPPFET S
            ========== =
HITS AT:  1-11
```

Seq. 19

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 21 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN **216489-79-1** REGISTRY
CN L-Serinamide, N-acetyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L-α-glutamyl-L-threonyl-, phenylmethyl ester (9CI) (CA INDEX NAME)
SQL 9

SEQ 1 LGRPPFETS
========
HITS AT: 1-9

Seq. 18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 22 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216489-77-9** REGISTRY
CN L-α-Glutamine, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-lysyl-L-prolyl-L-prolyl-L-phenylalanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)
SQL 9

SEQ 1 MLLGKPPFE
========
HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 23 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216489-75-7** REGISTRY
CN L-Phenylalaninamide, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-lysyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: US20020049301 SEQID: 16 claimed protein
SQL 8

Seq. 16

SEQ 1 MLLGKPPF
========
HITS AT: 1-8

REFERENCE 1: 136:335268

REFERENCE 2: 130:22236

L4 ANSWER 24 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216489-73-5** REGISTRY
CN L-α-Glutamine, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: US20020049301 SEQID: 15 claimed protein
SQL 9

SEQ 1 MLLGRPPFE
========
HITS AT: 1-8

REFERENCE 1: 136:335268

REFERENCE 2: 130:22236

L4 ANSWER 25 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **148466-70-0** REGISTRY
CN Kinase (phosphorylating), protein (mouse clone 2 isoenzyme Snk reduced) (9CI) (CA INDEX NAME)
CI MAN
SQL 682

SEQ
```
      1 MELLRTITYQ PAAGTKMCEQ ALGKACGGDS KKKRPQQPSE DGQPQAQVTP
     51 AAPHHHHHHS HSGPEISRII VDPTTGKRYC RGKVLGKGGF AKCYEMTDLT
    101 NNKVYAAKII PHSRVAKPHQ REKIDKEIEL HRLLHHKHVV QFYHYFEDKE
    151 NIYILLEYCS RRSMAHILKA RKVLTEPEVR YYLRQIVSGL KYLHEQEILH
    201 RDLKLGNFFI NEAMELKVGD FGLAARLEPL EHRRRTICGT PNYLSPEVLN
    251 KQGHGCESDI WALGCVMYTM LLGRPPFETT NLKETYRCIR EARYTMPSSL
                              = ========
    301 LAPAKHLIAS MLSKNPEDRP SLDDIIRHDF FLQGFTPDRL SSSCCHTVPD
    351 FHLSSPAKNF FKKAAAALFG GKKDKARYND THNKVSKEDE DIYKLRHDLK
    401 KVSITQQPSK HRADEEPQPP PTTVARSGTS AVENKQQIGD AIRMIVRGTL
    451 GSCSSSSECL EDSTMGSVAD TVARVLRGCL ENMPEADCIP KEQLSTSFQW
    501 VTKWVDYSNK YGFGYQLSDH TVGVLFNNGA HMSLLPDKKT VHYYAELGQC
    551 SVFPATDAPE QFISQVTVLK YFSHYMEENL MDGGDLPSVT DIRRPRLYLL
    601 QWLKSDKALM MLFNDGTFQV NFYHDHTKII ICNQSEEYLL TYINEDRIST
    651 TFRLTTLLMS GCSLELKNRM EYALNMLLQR CN
```
HITS AT: 270-277

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 119:44118

FILE 'HOME' ENTERED AT 14:29:31 ON 14 NOV 2003